关于我国药典重组DNA技术产品总论的思考

doi:10.13523/j.cb.20140515

中国生物工程杂志

2014, Vol. 34

Issue (5): 107-115 DOI: 10.13523/j.cb.20140515

医药生物技术专栏

关于我国药典重组DNA技术产品总论的思考

高凯¹, 任跃明², 王兰¹, 郭中平², 王军志¹

1 中国食品药品检定研究院北京 100050;
2 国家药典委员会北京 100061

Points to Consider for the General Monograph of Products Rrepared by Recombinant DNA Technology in Chinese Pharamacopeia

GAO Kai¹, REN Yue-ming², WAN Lan¹, GUO Zhong-ping², WANG Jun-zhi¹

1 Chinese National Institute for Food and Drug Control, Beijing 100050;
2 Chinese Pharmacopoeia Commission, Beijing 100061

全文: PDF(955 KB) HTML

摘要：

自1982年全球第一个生物技术药物“基因重组人胰岛素”、1989年中国批准第一个生物技术药物“重组人干扰素α1b”上市以来，生物技术药物已成为制药业中发展最快、活力最强和技术含量最高的领域。药品的规范生产与质量控制与其安全有效性密切相关，欧美药典中均设有对此类药品质量控制的总体要求。《中国药典》2010版三部已收录包括12类共计34个品种的重组DNA技术产品各论，在进一步保障药品安全、提高质量控制水平的编制指导思想下，《中国药典》2015版拟纳入对重组DNA技术产品的总体要求，本文就相关起草工作从产品涉及范畴、制造与产品检定等方面进行阐述。

关键词： 重组DNA技术; 生物技术药物; 生物治疗药物; 药典标准

Abstract:

Since the first biopharmaceutical—"recombinant human insulin" was licensed by US FDA in 1982, and "recombinant human interferon α1b", the first biopharmaceutical in China was approved in 1989, biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive field. Good manufacture practice and quality control are key contributions to the safety and efficacy of these drugs. General requirements for the control of monoclonal antibodies are embodied in European and United States Pharmacopeia. Currently there are 12 product categories and 34 monographs embodied in Chinese Pharmacopeia volumn Ⅲ edition 2010. In the coming new 2015 edition, a general monograph of products prepared by recombinant DNA technology is intend to be drafted and included under the directions to further improve drug safety as well as to upgrade the technology level of quality control. This paper is to pave the way for the drafting of monograph of recombinant DNA products from the aspects including scope, manufacture and release control etc.

Key words: Recombinant DNA technology Recombinant DNA products Biotherapeutics Pharmacopeia specification

收稿日期: 2014-01-20 出版日期: 2014-05-25

ZTFLH:

R917

基金资助:

国家科技重大专项课题资助项目（2014ZX09304311-001、2012ZX09304010）

通讯作者: 郭中平，王军志 E-mail: guozhongping@chp.org.cn；wangjz@nifdc.org.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

高凯, 任跃明, 王兰, 郭中平, 王军志. 关于我国药典重组DNA技术产品总论的思考[J]. 中国生物工程杂志, 2014, 34(5): 107-115.

GAO Kai, REN Yue-ming, WAN Lan, GUO Zhong-ping, WANG Jun-zhi. Points to Consider for the General Monograph of Products Rrepared by Recombinant DNA Technology in Chinese Pharamacopeia. China Biotechnology, 2014, 34(5): 107-115.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20140515 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I5/107

[1] General monograph: Recombinant DNA technology products. In: European Pharmacopoeia 7.0, 2011: 692-693.

[2] General Chapters: <1045> Biotechnology-derived articles. In: United States Pharmacopoeia 34, 2010.

[3] WHO. Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology. No.814. http://www.who.int/bloodproducts/publications/WHO_TRS_814_A3.pdf; 1991.

[4] WHO. WHO guidelines on the quality, safety, and efficacy of biotherapeutic products prepared by recombinant DNA technology. http://www.who.int/biologicals/WHO_rDNA_2nd_public_consultation_28_June_2013.pdf; 2013.

[5] European Medicine Agency (EMA). Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Qualityissues. 22/02/2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf.

[6] European Medicine Agency (EMA). Guideline on similar biological medicinal products. 30/10/2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.

[7] European Medicine Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 22/2/2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.

[8] WHO. Expert committee on biological standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf; 2009.

[9] FDA. Biosimilars:questions and answers regarding implementation of the biologics price competition and innovation act of 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM273001.pdf; 2012.

[10] FDA. Quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf; 2012.

[11] FDA. Scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf; Feb, 2012.

[12] ICH. Quality guidelines. Quality of biotechnological products Q5A, viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf. 23/09/1999.

[13] ICH. Quality guidelines. Quality of biotechnological products Q5B, quality of biothechnological products: analysis of the expression construct in cells used for production of r-DNA derived protein products. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5B/Step4/Q5B_Guideline.pdf. 30/11/1995.

[14] ICH. Quality guidelines. Quality of biotechnological products Q5D, derivation and characterization of cell substrates used for production of biothechnological/biological products. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf. 16/07/1997.

[15] ICH. Quality guidelines. Quality of biotechnological products Q5E, comparability of biotechnological/biological products subject to changes in their manufacturing process. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. ICH, 18/11/2004.

[16] 王军志. 生物技术药物研究开发和质量控制.第二版.北京:科学出版社, 2007. Wang J ZH. Development and Quality Control of Biopharmaceuticals. 2^rd Beijing:Science Press, 2007.

[17] ICH. Pharmaceutical development Q8. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf. Aug, 2009.

[18] ICH. Quality guidelines. Specifications Q6B, specification: test procedures and acceptance criteria for biothechnological/ biological products. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf. 10/03/1999.

[19] ICH. Quality risk management Q9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf. 09/11/2005.

[20] ICH. Pharmaceutical quality system Q10. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf. 04/06/2008.

[21] General Chapters: <1046> Cell and gene therapy products. In: United States Pharmacopoeia 34, 2010.

[1]	王兰, 徐刚领, 高凯, 王军志. 抗体类生物治疗药物活性测定方法[J]. 中国生物工程杂志, 2015, 35(6): 101-108.
[2]	毛开云, 杨露, 王恒哲, 陈大明. 生物技术药物市场现状与发展趋势[J]. 中国生物工程杂志, 2015, 35(1): 111-119.
[3]	高凯, 徐志凯, 任跃明, 王兰, 王军志, 郭中平. 关于我国药典单克隆抗体类生物治疗药物总论的思考[J]. 中国生物工程杂志, 2014, 34(1): 127-134.
[4]	文淑美. 全球生物制药产业发展态势[J]. 中国生物工程杂志, 2006, 26(01): 92-96.
[5]	胡显文, 陈惠鹏, 汤仲明, 马清钧. 美国、欧盟和中国生物技术药物的比较[J]. 中国生物工程杂志, 2005, 25(02): 82-94.
[6]	汪小凤, 郑青. 生物技术药物药代动力学研究的方法学和实验设计[J]. 中国生物工程杂志, 2004, 24(2): 80-83,87.
[7]	丁锡申. 生物技术药物产业化发展的新趋势[J]. 中国生物工程杂志, 2004, 24(11): 96-97.
[8]	陆仁. 澳大利亚生物技术印象──中国科学院生物技术专家组赴澳大利亚考察报告[J]. 中国生物工程杂志, 1994, 14(5): 19-22.
[9]	JamesB.Wyngaarden, 袁萍. 健康和技术[J]. 中国生物工程杂志, 1992, 12(5): 33-39.
[10]	江北. 《大规模哺乳动物细胞培养技术》[J]. 中国生物工程杂志, 1992, 12(4): 64-64.
[11]	江北. 《大规模哺乳动物细胞培养技术》[J]. 中国生物工程杂志, 1992, 12(3): 64-64.
[12]	MooJeCho, 王连琴. 南朝鲜遗传工程与生物技术的现状[J]. 中国生物工程杂志, 1992, 12(1): 35-40.
[13]	罗登. 当前生物技术发展的三个趋向[J]. 中国生物工程杂志, 1991, 11(3): 1-7.
[14]	. 动物细胞生物工程第3卷[J]. 中国生物工程杂志, 1990, 10(4): 53-53.
[15]	韩迎山. 美创造出脓毒性咽喉炎重组疫苗[J]. 中国生物工程杂志, 1990, 10(1): 60-61.

Viewed

Full text

Abstract

Cited

Shared

Discussed